GREY:IMVIQ - Post by User
Comment by
qwerty22on Nov 12, 2020 12:41pm
127 Views
Post# 31885699
RE:The pembro trial may be...
RE:The pembro trial may be... I think that trial data and second link is first-line treatment which is different to r/r and has generally better outcomes as well. That's not comparable.
The first link is the trial the analyst mentioned the ongoing pembro trial in pd-l1+ patients but I guess the data from that isn't public. If Merck have that data then the head-to-head with pembro+dpx is the best comparable.
Breakthorough wrote: https://www.clinicaltrials.gov/ct2/show/NCT03990961?term=Pembrolizumab&cond=DLBCL&draw=2&rank=1 Or this: "The overall and complete response rate was 90% and 77%. With 255 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS." https://pubmed.ncbi.nlm.nih.gov/32030732/